Lux Capital

Lux Capital is a stage-agnostic venture firm focused on frontier science and deep technology, investing globally from first experiments through growth rounds. The firm is known for high-conviction bets on technically difficult, non-consensus companies in areas like defense, AI, biotech, aerospace, and industrial systems—backing founders who can turn "sci-fi into sci-fact."

Evaluation weights

How much weight this investor places on each dimension. Totals 100%.

Market-led · 35%

Metrics

Revenue, growth, and unit economics

Market

35%

Size, timing, and competitive landscape

Team

31%

Founder experience and execution ability

Product

27%

Differentiation and technical quality

Strong bias toward technical depth over early commercial polish
Willingness to underwrite technology risk when the team is exceptional
Preference for non-consensus categories rather than consensus momentum trades
More receptive to hard-tech, dual-use, and science-heavy businesses than most generalist VCs

Pitch difficulty

How hard it is to get a meeting and close funding from this investor.

Funded / yr

Deals closed in a typical year.

Led / yr

Rounds led in the last 12 months.

Pitches / yr

~2067

Decks reviewed in a typical year.

Acceptance rate

1.5%

Share of pitches that get funded.

Estimated — public data is not fully disclosed.

Why it's hard

Focus on rare, technically elite founders in difficult domains
Preference for non-incremental companies with hard scientific or engineering moats
High-conviction style means fewer but deeper bets
Strong bias toward category-defining outcomes in massive frontier markets

Lux is highly selective because it targets a narrow set of founder and company profiles: exceptional technical teams building breakthrough deep-tech businesses with potential for category-defining outcomes. Its broad stage range and large check flexibility increase relevance, but the bar for technical originality, ambition, and founder-market fit is unusually high.

Green flags

What drives a yes for this investor.

A rare technical moat rooted in real science or engineering advantage
Founders with exceptional domain credibility, often deeply technical specialists
A non-consensus thesis in a market others may misunderstand or undervalue
Potential to become foundational infrastructure or a category-defining platform
Evidence that compute, automation, or biology creates asymmetric leverage

Red flags

What kills deals and gets a fast no.

Incremental products in crowded markets without a hard technical edge
Founders lacking deep domain credibility in highly technical categories
AI or biotech narratives that are mostly hype and light on proprietary substance
No clear path from research novelty to real-world deployment or commercialization
Small-market opportunities that cannot justify Lux's ambition and conviction

How to win

Patterns that lead to successful pitches.

Lead with the breakthrough: explain the technical moat in concrete scientific or engineering terms
Show why this team is uniquely qualified to solve the problem, not just interested in it
Frame the opportunity as a non-consensus but massive market that could become critical infrastructure
Present milestone evidence that de-risks the core science, even if revenue is still minimal
Demonstrate a credible path from frontier technology to a durable platform business

Fund strategy & identity

Who they are and how they operate.

Invest across the full company lifecycle, from pre-revenue formation to large growth rounds
Back companies with hard technical moats in science, engineering, biology, and compute
Lead rounds aggressively with flexible check sizes from small seed checks to very large financings
Favor misunderstood or nascent markets over crowded, incremental categories
Support category creation where breakthrough technology can become critical infrastructure

Firm identity

Frontier science and deep-tech specialist High-conviction, lead-oriented investor Stage-agnostic from pre-seed to growth Non-consensus and thesis-driven Global firm with strong U.S. roots in New York and Silicon Valley

Investment focus

Industries, themes, and typical ARR expectations.

Industries

Artificial IntelligenceBiotechnologyDefense and National SecurityAerospace and SpaceIndustrial AutomationTransportation and AutonomyAdvanced ManufacturingSensing and Technical Infrastructure

Investment themes

Defense, national security, and dual-use autonomyAI infrastructure, foundation models, and applied machine intelligenceBiotech, therapeutics platforms, and computational biologyAerospace, space systems, and advanced manufacturingIndustrial automation, robotics, and autonomous factoriesCross-disciplinary science combining chemistry, materials, and AICore sensing, compute, and technical infrastructure

Typical check by stage

Pre Seed$0.1M-$5M

Seed$2M-$10M

Series A$5M-$25M

Series B$10M-$50M

Series C$15M-$75M

Growth$25M-$100M+

Typical ARR by stage

Pre Seed$0

Seed$0-$1M

Series A$0-$3M

Series B$3M-$15M

Series C$10M-$50M

Growth$20M-$100M+

Investment thesis

Core beliefs and strategy behind their investing approach.

Lux Capital backs frontier science and technology across sectors such as aerospace, biotechnology, defense and national security, industrial automation, transportation, data & AI, sensing, and related deep‑tech domains. Their core belief is turning "sci‑fi into sci‑fact" by partnering with founders who have rare technical expertise and are tackling problems where compute, automation, or biology can generate asymmetrical advantages. Lux is stage‑agnostic, deploying checks from $100 K up to $100 M and staying invested from the earliest experiments through large growth rounds. Geographically, the firm is global, anchored in New York with a Silicon Valley office, and it invests in companies worldwide. While it does not publish a formal anti‑thesis, Lux avoids overly crowded, incremental markets lacking a hard technical edge, focusing instead on non‑consensus categories where markets are misunderstood or nascent. This thesis drives a long‑term partnership model that treats capital as a tool to scale breakthrough science into enduring businesses.

Decision patterns

How they evaluate and make investment decisions.

Lux invests when a startup demonstrates a deep technical moat and is led by founders with rare domain expertise—often PhDs or seasoned engineers—pursuing hard problems where compute, automation, or biology create asymmetry. The firm favors non‑consensus theses and technologies that could become critical infrastructure, such as national‑security AI platforms or novel therapeutics. In evaluating deals, Lux places the team and technology above early market traction; at seed stage it will back pre‑product, pre‑revenue companies based on scientific merit, while later stages require clear productization, strategic contracts, or milestone achievements. Deal‑breakers include incremental offerings lacking a hard technical edge, overly crowded markets, and weak founder‑market fit in highly technical domains.

Risk appetite

Lux Capital exhibits an aggressive, conviction‑driven risk appetite. The firm regularly leads rounds—from seed checks of $100 K to massive $100 M investments—showing comfort with pre‑revenue, pre‑product companies, especially in frontier AI, defense, and biotech. Its stage‑agnostic mandate and willingness to commit large capital when it believes in a technology’s long‑term impact place it on the aggressive side of the risk spectrum, favoring lead positions over passive follow‑on investments.

Notable investments

Key portfolio companies and why they fit the thesis.

Hugging FaceLead
Open–source NLP platform core to the AI ecosystem, matching Lux’s AI/infra frontier thesis.
MatterportLead
3D capture of the built world combines computer vision and hardware at scale, fitting Lux’s deep–tech focus.
Auris HealthLead
Transformational surgical–robotics company at the intersection of AI and biotech, aligned with Lux’s health–tech frontier agenda.
HadrianLead
Autonomous, software–defined factories for precision defense/space components, exemplifying Lux’s industrial–automation thesis.
Applied IntuitionLead
Vehicle–intelligence and autonomy tooling that brings AI software into large–scale automotive and aerospace markets.
OsmoLead
AI–powered fragrance design merges machine learning with chemistry, a novel frontier application of AI.
KallyopeLead
Platform biotech unlocking the gut–brain axis, reflecting Lux’s science–driven biotech investments.
Benchling
Life–sciences R&D cloud provides data infrastructure for biotech, fitting Lux’s health–tech interest.
Runway
Next–gen creative AI tools align with Lux’s support for frontier AI applications.
Databricks
Core data–plus–AI platform that backs many of Lux’s AI–focused investments.

Key people

Partners who lead investments and shape the thesis.

JW
Josh Wolfe
Co-Founder & Managing Partner
AIRoboticsSpaceBiotech
PH
Peter Hébert
Co-Founder & Managing Partner
Frontier technologyDeeptech
SF
Shahin Farshchi, PhD
General Partner
AIAutomationDefenseEnergyInfrastructureRobotics
DS
Deena Shakir
General Partner
Women's healthDigital health infrastructureFoodtechFintech
BZ
Bilal Zuberi
Co-President & General Partner
DeeptechIndustrial AIHardware

Public voice

Notable statements and public positions.

"We believe before others understand."
"Some firms don’t take technology risk. I don’t think they should call themselves venture capitalists… The best definition of risk is that more things can happen than will."
"For these businesses and founders to become category‑defining winners, they need meaningful capital and conviction… a $1.5B commitment to investing in the people turning sci‑fi into sci‑fact."